Related Experiment Video

Updated: Jun 23, 2026

Analysis of Cell Cycle Position in Mammalian Cells
12:19

Analysis of Cell Cycle Position in Mammalian Cells

Published on: January 21, 2012

E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8

Erick J Morris1, Jun-Yuan Ji, Fajun Yang

  • 1Laboratory of Molecular Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, 13th Street, Building 149, Charlestown, Massachusetts 02129, USA.

Nature
|September 17, 2008
PubMed

Insights

The E2F1 transcription factor inhibits beta-catenin/T-cell factor (TCF) activity, promoting apoptosis. Colorectal tumors maintain RB1 and amplify CDK8 to suppress E2F1, enhancing beta-catenin-driven proliferation.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Cell Signaling

Background:

  • The E2F1 transcription factor, a downstream target of the retinoblastoma tumor suppressor protein (pRB), plays a critical role in regulating cell proliferation and apoptosis.
  • Beta-catenin/T-cell factor (TCF) signaling is crucial for the aberrant proliferation observed in many cancers, particularly colorectal tumors.

Purpose of the Study:

  • To investigate the inhibitory role of E2F1 on beta-catenin/TCF-dependent transcription.
  • To elucidate the mechanisms by which E2F1 influences colorectal tumor cell behavior.
  • To understand how colorectal tumors evade E2F1-mediated apoptosis and maintain proliferation.

Main Methods:

  • Assessed the inhibitory effect of E2F1 on beta-catenin/TCF transcriptional activity.
  • Examined the impact of E2F1 deregulation on beta-catenin targets, such as c-MYC.
  • Investigated the role of cyclin-dependent kinase-8 (CDK8) in modulating E2F1 activity and beta-catenin signaling.

Main Results:

  • E2F1 was identified as a potent and specific inhibitor of beta-catenin/TCF-dependent transcription, contributing to E2F1-induced apoptosis.
  • E2F1 deregulation suppressed beta-catenin activity independently of APC/GSK3, leading to reduced c-MYC expression.
  • Colorectal tumors maintain RB1 and amplify CDK8, which represses E2F1 activity, thereby protecting beta-catenin/TCF signaling.

Conclusions:

  • E2F1's inhibition of beta-catenin/TCF signaling is a key mechanism contributing to E2F1-induced apoptosis.
  • Colorectal tumor cells utilize RB1 retention and CDK8 amplification to suppress E2F1, promoting beta-catenin-driven proliferation.
  • These findings provide insights into the intricate interplay between E2F1, beta-catenin, and CDK8 in colorectal tumorigenesis.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Catenins01:23

Catenins

Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the adherens...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...